Michael O. Daines, MD

Michael O. Daines, MD, division chief, Pediatric Allergy and Immunology, University of Arizona College of Medicine; Principal investigator, phase 3 study of Panzyga for PANS.

Articles by Michael O. Daines, MD

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

ByMichael O. Daines, MD

June 19th 2025

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

ByMichael O. Daines, MD

June 12th 2025

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.

Latest Updated Articles

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Published: June 19th 2025 | Updated:
Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome
Published: June 12th 2025 | Updated:

Michael O. Daines, MD

Articles by Michael O. Daines, MD

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

Latest Updated Articles

Trending on Contemporary Pediatrics

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD